SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Epic Bio, a leading epigenome engineering company developing therapies to modulate gene expression using ultracompact, non-cutting dCas proteins, today announced that the company will participate in the Guggenheim Healthcare Talks - Genomic Medicine and Rare Disease Days, April 3-4, 2023, in New York, NY. The company will also hold meetings with investors and analysts during the event.
Amber Salzman, Ph.D., Epic Bio’s chief executive officer, is scheduled to participate in a panel on genomic medicines and rare diseases on Monday, April 3, 2023, from 1:00 – 2:00 p.m. ET.
About Epic Bio
Epic Bio is a leading epigenome engineering company, leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through the company’s library of the most compact Cas DNA-binding proteins to work on human cells, the company is developing in vivo therapies leveraging delivery via a single AAV or LNP. Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypocholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epic-bio.com for more information or follow us on Twitter and LinkedIn.
Contacts
Investor Contact
Shawn M. Cox
Manager, Investor Relations, Corporate Communications
Epic Bio
Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783
